Virax Biolabs Group Limited
- VRAX
- NASDAQ
- Biotechnology
- T-cell Diagnostics
- Infectious Disease Testing
$1.40
Today −3.45%Quote Oct 19, 2026, 08:00 PM UTC
−44.88%over the last month
Max drawdown −45.1%From 1-month high −45.1%3 months −63.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Virax Biolabs
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
26
Market value
$810,905.2
Quote Oct 19
Analyst target
$1.00
−28.6% from here
Floor
$1.34
4.3% below price
Resistance
$2.34
67.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VRAXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free